Have you been diagnosed with primary central nervous system (CNS) lymphoma? If so you may be able to take part in a research study looking at whether using the study drugs lenalidomide, and nivolumab can be safely used in addition to the standard treatment of primary CNS lymphoma, and which dose is the most adequate when they are used together.

The purpose of this study is to test whether giving the study drug acalabrutinib is safe and could help control B-cell Non-Hodgkin CNS lymphoma that have not gone away, or have come back, after the first round of treatment.

The purpose of this research study is to deliver 6 months of 1:1 health coaching to cancer patients being treated at UNC Cancer Hospital. This program hopes to improve patient's self-confidence and satisfaction with how they feel and what they are able to do day-to-day. This includes exercising, support for healthy eating, emotional and social needs. Health coaching means you will receive weekly phone calls and emails from a trained coach.

Do you have Peripheral T Cell Lymphoma? Has your cancer come back or did it not get better with the last treatment you were given? If so, you may be eligible to participate in this gene therapy research study to learn more about using your own modified immune cells as possible treatment.

Researchers are studying different doses of a therapy (CD19 CAR T-cells) to find the dose that is both the most effective and the safest for patients with relapsed or refractory B-cell lymphoma.

The purpose of this study is to establish a safe dose of study cells (ATLCAR.CD30.CCR4 and ATLCAR.CD30) to give to patients with CD30+ refractory/relapsed Hodgkin's Lymphoma and Cutaneous T-Cell Lymphoma.

The purpose of this study is to establish a safe dose of study cells (ALTCAR.CD30) to give after chemotherapy and estimate progression free survival in pediatric patients with CD30+ refractory/relapsed Hodgkin lymphoma (HL) and non-Hodgkin lymphoma.

This study seeks to better understand the unmet needs and care preferences of young adult cancer patients and their caregivers. Interviews to gather this information will be used to tailor an existing, evidence-based patient navigation program to these needs and preferences.

The overall objective of this project is to examine differences in performance fatigability and contributing mechanisms between firefighters in cancer remission and healthy firefighter controls. Findings from this research project will inform future interventions to reduce CRF in firefighters in cancer remission.

The purpose of this study is to measure the effect of 30 mg RE104 on adjustment disorder symptoms (depressed mood or anxiety) compared to 1.5 mg RE104 in participants with cancer or other illnesses in order to decrease these symptoms.